Arcutis Canada, a subsidiary of Arcutis Biotherapeutics (ARQT), said Monday it has received approval from Health Canada for Zoryve to treat seborrheic dermatitis in patients aged 9 and older.
Trial data showed notable improvement in signs and symptoms, with the majority of patients experiencing reduced itching, scaling and redness, common burdens associated with seborrheic dermatitis, the company said.
Shares of the company were about 2% lower in recent trading.
Price: 8.56, Change: -0.16, Percent Change: -1.83
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.